They offer a range of products and services to detect and treat cancer at the cellular level. Their flagship product, CyPath® Lung, is a groundbreaking test that accurately diagnoses early-stage lung cancer, which is the leading cause of cancer-related deaths. This innovative test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test.

CyPath® Lung is a non-invasive test that assists in clinical decision-making for lung cancer patients who have received a suspicious but indeterminate low-dose computed tomography (LDCT) result. By analyzing sputum using advanced flow cytometry, CyPath® Lung reveals important information about the lung micro-environment, identifying cell populations indicative of cancer in the lung. By offering at-home sample collection kits and advanced flow cytometry analysis, bioAffinity Technologies aims to increase overall diagnostic accuracy, leading to increased survival rates, fewer unnecessary invasive procedures, and reduced patient anxiety and medical costs.

With their ongoing research and development efforts, bioAffinity Technologies continues to expand their core porphyrin platform technology to create targeted diagnostics and therapeutics in the fight against cancer